<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04811443</url>
  </required_header>
  <id_info>
    <org_study_id>BCD-017-01-NIS</org_study_id>
    <nct_id>NCT04811443</nct_id>
  </id_info>
  <brief_title>DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs</brief_title>
  <acronym>DEFENDOR</acronym>
  <official_title>DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biocad</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biocad</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study was designed to evaluate the efficacy and safety of Extimia® (INN -&#xD;
      empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile&#xD;
      neutropenia and infections caused by febrile neutropenia in patients with solid tumours&#xD;
      receiving myelosuppressive therapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 12, 2021</start_date>
  <completion_date type="Anticipated">June 12, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 12, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Relative dose-intensity (RDI) of the myelosupressive therapy course</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The incidence of febrile neutropenia with empegfilgrastim supportive therapy compared with historical control</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of neutropenia leading to a dose reduction of cytostatic drugs and / or an increase of the interval between cycles when using empegfilgrastim supportive therapy compared with historical controls</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of chemotherapy courses performed in relation to nosology</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RDI of chemotherapy courses performed in relation to treatment regimen</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Any grade adverse events frequency</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Grade 3-4 adverse events frequency</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse events frequency</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of study withdrawal due to adverse events</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of severe infections (grade 3-4)</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of antibiotic prescription</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Patients With Solid Tumours Who Receive Myelosupressive Therapy</condition>
  <arm_group>
    <arm_group_label>Patients with solid tumors who have received myelosupressive therapy</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Empegfilgrastim</intervention_name>
    <description>Extimia®</description>
    <arm_group_label>Patients with solid tumors who have received myelosupressive therapy</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with solid tumors who are prescribed myelosuppressive therapy with empegfilgrastim&#xD;
        supportive therapy to reduce the frequency, duration of neutropenia, the incidence of&#xD;
        febrile neutropenia (FN) and infections manifested by FN, as part of routine clinical&#xD;
        practice according to the approved indications of the appropriate drugs.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed informed consent form;&#xD;
&#xD;
          2. Histologically verified diagnosis;&#xD;
&#xD;
          3. Age between 18 and 80 years;&#xD;
&#xD;
          4. If the patient had previously received chemotherapy for these indications, then it&#xD;
             should be completed at least 30 days before the first administration of the study&#xD;
             drug;&#xD;
&#xD;
          5. ECOG performance 0-2;&#xD;
&#xD;
          6. Haematology:&#xD;
&#xD;
               -  ANC ≥ 1,5 х 10(9) /L;&#xD;
&#xD;
               -  Platelets ≥ 100 х 10(9) /L;&#xD;
&#xD;
               -  Hemoglobin ≥ 90 g/L;&#xD;
&#xD;
          7. Biochemistry:&#xD;
&#xD;
               -  Creatinine ≤ 1,5 ULN;&#xD;
&#xD;
               -  Total bilirubin ≤ 1,5 ULN;&#xD;
&#xD;
               -  AST/ALT ≤ 2,5 ULN;&#xD;
&#xD;
               -  Alkaline phosphatase ≤ 5 ULN;&#xD;
&#xD;
          8. Life expectancy of at least 6 months from the date of the first drug administration in&#xD;
             the study;&#xD;
&#xD;
          9. Ability of the patient to comply with the Protocol requirements.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented hypersensitivity to empegfilgrastim, filgrastim, pegfilgrastim, and / or&#xD;
             their constituent excipients: pegylated drugs, protein recombinant drugs;&#xD;
&#xD;
          2. Systemic use of antibiotics less than 72 hours before the first drug administration in&#xD;
             the study;&#xD;
&#xD;
          3. Concurrent or less than 30 days before the start of the study, radiation therapy (with&#xD;
             the exception of point radiation therapy for bone metastases); study;&#xD;
&#xD;
          4. Concurrent participation in clinical trials, participation in clinical trials within&#xD;
             the previous 30 days, previous participation in this study;&#xD;
&#xD;
          5. Surgical treatment less than 21 days (3 weeks) prior to study enrollment; taking any&#xD;
             experimental medications less than 30 days before enrollment in this study;&#xD;
&#xD;
          6. History of bone marrow or hematopoietic stem cell transplantation;&#xD;
&#xD;
          7. Presence of acute or active chronic infections;&#xD;
&#xD;
          8. Other diseases (with the exception of the main one) that could affect the assessment&#xD;
             of the severity of the symptoms of the underlying disease: that may mask, enhance,&#xD;
             change the symptoms of the underlying disease or cause clinical manifestations and&#xD;
             changes in the data of laboratory and instrumental research methods;&#xD;
&#xD;
          9. Inability to administer the drug by intravenous infusion or subcutaneous injection.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Irina Sorokina, PhD</last_name>
    <phone>+7 (812) 380 49 33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Irina Khlopotkina, MD</last_name>
    <phone>+7 (812) 380 49 33</phone>
    <email>biocad@biocad.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Regional Clinical Oncology Hospital</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavskaya Oblast</state>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nikolay V Kislov, MD, PhD</last_name>
      <phone>+7-(812)-380-49-34</phone>
      <email>biocad@biocad.ru</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Josaphat Belgorod Regional Clinical Hospital</name>
      <address>
        <city>Belgorod</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>State Health Institution &quot;Voronezh Region Clinical Oncology Dispansary&quot;</name>
      <address>
        <city>Voronezh</city>
        <zip>394000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 19, 2021</study_first_submitted>
  <study_first_submitted_qc>March 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 23, 2021</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

